 In Australia, PrEP drugs were available, at "about $1,200 per month", following the May 2016 approval of the Therapeutic Goods Administration.Despite the lobbying to have these PrEP drugs subsidised under the Pharmaceutical Benefits Scheme, in August 2016 it was announced that the Pharmaceutical Benefits Advisory Committee had rejected the proposal for this drug to be PBS-subsidised.On 9 February 2018, the Pharmaceutical Benefits Advisory Committee (PBAC) announced that PrEP will be subsidised by the Australian Government through the Pharmaceutical Benefit Scheme (PBS).